ISPOR Health Economics and Outcomes Research - Application Award
Dan Greenberg, PhD, Associate Professor and Chairman, Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel
ISPOR Health Economics and Outcomes Research - Application Award was established in 1997 to recognize outstanding practical application of pharmacoeconomics and outcomes research in health care decision-making.
The award is given to a distinguished example of applied health outcomes research that has or is expected to have a high impact on health policy or healthcare decision making. Preference is given to papers with creative application of health outcomes research, encompassing topics such as health policy, evaluation and adoption of health technologies, and other issues that further the goals and objectives of the Society. The award is selected by the ISPOR Excellence Awards Committee from nominated papers that have appeared in print or e-pub in peer-review journals during the preceding calendar year (e-pub must be listed in Medline) and other communication venues (e.g. books, reports). Self-nominations are encouraged and accepted for consideration.
A candidate may only be nominated for one major ISPOR award in a year.
A call for nominations is placed in November-December Value & Outcomes Spotlight for articles published during the past twelve months to be considered for the ISPOR Health Economics and Outcomes Research - Application Award. In addition, each Excellence Award Committee member selects relevant publications in respected peer-reviewed journals during the preceding twelve months to be considered by the Awards Committee in the selection process. The Excellence Award Committee meets via teleconference in February to discuss each of the nominated publications. They select the best demonstration of scientific excellence for that time period. The nominee is then forwarded to the Board of Directors for final approval. The corresponding author on the publication is given the award.
Nature of Award:
The Award, presented at the ISPOR Annual International Meeting to the corresponding author of the paper, consists of a plaque, complimentary Annual International Meeting registration, roundtrip air fare, hotel, meal and miscellaneous expenses for two days, based upon current ISPOR travel policies.
Nominations for the ISPOR Health Economics and Outcomes Research - Application Award should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and sent to email@example.com. Only ISPOR members may submit nominations (either their own publications or others).
Rebecca Myerson, MPH, PhD,
School of Pharmacy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, Los Angeles, CA, USA
For the paper, “Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York,” JAMA Cardiol 2017;2:627-634.
Rebecca Myerson, MPH, PhD, is an assistant professor at the University of Southern California and affiliate of USC’s Schaeffer Center for Health Policy and Economics. She holds a PhD in public policy with a concentration in applied econometrics from University of Chicago and an MPH from University of Washington. With the goal of informing policy to improve health, her research aims to quantify the impacts of policies on incidence and treatment of diabetes and cardiovascular disease. Her health economics research assesses whether informing patients about their health biomarkers and health insurance options closes gaps in uptake of needed care. Specific projects have analyzed trans fat restrictions, screening interventions, assistance programs for health insurance enrollment, and Medicaid eligibility expansions. Rebecca has received research funding from the Agency for Healthcare Research and Quality and a Fulbright Scholarship. Rebecca gratefully accepts this award on behalf of her coauthors, Eric Brandt, Marcelo Coca-Peraillon, and Tamar Polonsky.
Jeff Richardson, PhD,
Professor and Foundation Director, Centre for Health Economics, Monash University
For the paper, Measuring the Sensitivity and Construct Validity of 6 Utility Instruments in 7 Disease Areas,” Med Decis Making 2016;36:147–159.
Jeff Richardson, PhD, is a Professor and Foundation Director of the Centre for Health Economics at Monash University. He has held honorary positions at Stanford University, the Australian National University and the University of South Australia and worked as a consultant for the WHO, AusAID (the Australian foreign aid organization), and the Australian Government chairing a 2004 review of the Tasmanian health system. He was president of the Australian Health Economics Society for 7 years and a member of the tribunal, which determines pharmaceutical remuneration for 16 years. His research has included the earliest econometric modelling of the Australian health system and the first use of Cost Utility Analysis in Australia. This led to the development of the AQoL suite of utility instruments, the AQoL website and an ethical analysis of the QALY (a book co-authored with Peter Singer). Recent work has focused upon social preferences for health outcomes. He has 213 unrefereed research reports and 195 peer reviewed articles or book chapters.
Joshua J. Gagne, PharmD, ScD,
Assistant Professor of Medicine at Harvard Medical School and a pharmacoepidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital.
For the paper, " Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data" Value Health. 2015; 18:1063-1069.
Dr. Gagne is an Assistant Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School and an Assistant Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. His research focuses on methods for generating post-approval comparative safety and effectiveness evidence for new medical products. He is Co-Lead of the Methods Core of the FDA Sentinel program. He teaches courses in pharmacoepidemiology and comparative-effectiveness research at the Harvard T.H. Chan School of Public Health, where he co-directs the Pharmacoepidemiology Program. His research is funded by AHRQ, FDA, PCORI, and the Reagan-Udall Foundation. Dr. Gagne earned his PharmD degree from the University of Rhode Island College of Pharmacy and his ScD degree in Epidemiology from the Harvard T.H. Chan School of Public Health. He serves on the editorial boards of Drug Safety and Pharmacoepidemiology and Drug Safety.
Joshua A. Roth, PhD, MHA
Assistant Member, AHRQ Patient-Centered Outcomes Research K12 Scholar, Hutchinson Institute for Cancer Outcomes Research (HICOR), Fred Hutch, Seattle, WA, USA
For the paper, "Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study" Ann Intern Med. 2014;160:594-602.
Dr. Roth is an Assistant Member at the Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson Cancer Research Center, and an Affiliate Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. Additionally, he is currently an Agency for Healthcare Research and Quality K12 scholar in patient-centered outcomes research. Dr. Roth's primary research interest is application of comparative effectiveness research methods to inform translation of lung and breast cancer therapeutics and diagnostics, including: observational study design, decision modeling, randomized controlled trial design, systematic review, and meta-analysis. His current research focuses on evaluating patient perspectives on lung cancer screening, and applying value of information analysis to identify high-value study designs for future lung cancer screening research. Dr. Roth received his PhD in pharmaceutical outcomes research from the University of Washington. He also holds a MHA degree from the department of health services at the University of Washington.
Marta O. Soares, Researcher,Centre for Health Economics, University of York
For the paper, “Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse: Negative-Pressure Wound Therapy for Severe Pressure Ulcers” Med Decis Making 2013 33: 415.
Marta O. Soares, is a Researcher in the Centre for Health Economics at the University of York (https://www.york.ac.uk/che/staff/research/marta-soares/). She holds an MSc in Biostatistics awarded by the University of Lisbon in 2008. Marta is currently a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee.
Marta has worked on a variety of applied projects, in clinical areas including wound care, epilepsy and sepsis. She has carried out a range of methods research in areas including expert elicitation, evidence synthesis, decision modeling and value of information analysis. Marta has also been involved in policy-focused methods development including a framework to support decision making in the face of different types of evidential uncertainty and estimation of the NICE cost-effectiveness threshold.
For the paper, “Does Managed Care Affect the Diffusion of Psychotropic Medications?” Health Econ. 2012 Apr; 21(4):428-43.
Niteesh K. Choudhry, MD, PhD, Associate Professor, Harvard Medical School, Boston, MA, USA
For the paper, “Full Coverage for Preventive Medications after Myocardial Infarction” N Engl J Med 2011;365:2088-97.
Niteesh K. Choudhry, MD, PhD, is an internist and health services researcher whose work focuses on the clinical and economic consequences of evidence-based therapies for the management of common chronic conditions. He is particularly interested in the design and evaluation of novel strategies to overcome barriers to treatment initiation and long-term medication adherence. His work employs a broad range of methods including randomized policy evaluations, cost-effectiveness modeling, claims analyses, and surveys. Dr. Choudhry is an Associate Professor at Harvard Medical School and Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. He received his MD and completed his residency training in Internal Medicine at the University of Toronto, did his PhD in Health Policy at Harvard University and was a Fellow in Pharmaceutical Policy Research at Harvard Medical School. He practices inpatient general internal/hospital medicine and is actively involved in resident education.
Craig J. Currie, PhD
Reader in Diabetes Pharmacoepidemiology, Department of Primary Care and Public Health, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre, University Hospital of Wales, Cardiff, UK
Ties Hoomans PhD, MSc
Value of Information And Value Of Implementation: Application Of An Analytic Framework To Inform Resource Allocation Decisions In Metastatic Hormone-Refractory Prostate Cancer. Value Health 2009;12:315-24.
Maureen Rutten van Mölken PhD
Associate Professor Health Economics
Institute for Medical Technology Assessment
Erasmus University/Erasmus Medical Centre, Rotterdam, The Netherlands
For the paper, Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MPM. Expected Value of Perfect Information: An empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. Value in Health 2008;11:1070-80.
Greg Zaric PhD
For the paper, Zaric G, Brandeau ML. A little planning goes a long way: multilevel allocation of hiv prevention resources. Med Decis Making 2007;27:71-81.
John Hsu, MD, MBA, MSCE
Kaiser Division of Research
Kaiser Institute for Health Policy
For the paper, Hsu J, Price M, Huang J, et al. Unintended Consequences of Caps on Medicare Drug Benefits. N Engl J Med 2006;354:2349-59.
Josephine A. Mauskopf PhD
Economics MHA, Health Administration
For the paper, Mauskopf J, Kitahatan, Kauf T, et al. HIV antiretrovial treatment: early versus later. J Acquir Immune Defic Syndr 2005;9:562-69.
For the paper, Schneeweiss S, Dormuth C, Grootendorst P, et al. Clinical and economic consequences of a formulary restriction of nebulized respiratory drugs in adults: direct comparison of randomized and observational evaluations. Br Med J 2004:328:560-4.
Emily R. Cox, PhD
Director of Research
Office of Evidence Based Pharmacy Benefit Design
For the paper, Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost-effectiveness of cyclooxygenase 2 inhibitors (COX-2s). Am J Manag Care 2003;9:785-94.
Jean-Michel Gaspoz MD
Clinique de Medecine II and the Division of Cardiology
Hopitaux Universitaires, Geneva, Switzerland
For the paper, "Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease." New England Journal of Medicine. 2003;348:562-3.
Jean-Michel Gaspoz, MD, MSc, trained in general internal medicine and in cardiology at the University Hospitals of Geneva, Switzerland, as well as at New England Deaconess Hospital and Brigham and Women's Hospital, Boston, USA.
He is a former fellow in Clinical effectiveness of the Division of Clinical Epidemiology of Brigham and Women's Hospital, Boston, and holds a Master of Science degree in Health Policy and Management from the Harvard School of Public Health, Boston, USA. Dr Gaspoz is Assistant Professor of Medicine at the University of Geneva Medical School, Geneva, Switzerland, Associate Physician-in-chief of the Clinique de Médecine 2 (Division of General Internal Medicine) and Senior Consultant at the Cardiology Division, Department of Medicine, Geneva University Hospitals. His research has focused on health
David W. Baker MD, MPH
For the paper, Baker DW, Sudano JJ, Abert JM, et al. Lack of health insurance and decline in overall health in late middle age. N Eng J Med 2001;345:1106-12.
Jean M. Mitchell PhD
For the paper, Mitchell JM, KH Anderson. Effects of case management and new drugs on medicaid aids spending. Health Affairs 2000;19:233-43.
Michael K. Gould MD, MSc
For the paper, Gould MK, Dembitzer AD, Doyle RL, et al. Low-milecular-weight hearins compared with unfractioned heparin for treatment of acute deep venous thrombosis. Ann Internal Med 1999;130:789-9.
Sean Sullivan PhD
For the paper, Mather DB, Sullivan SD, Augenstein D, et al. Evaluation clinical outcomes and economic consequences for formulary decision: a practical approach. Am J Manag Care 1999;5:277-85.
Deborah J. Partsch PharmD
For the paper, Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential of oflaxin versus standard switch therapy. Ann Pharmacother 1997;31:1137-45.
Nelda Johnson PharmD
For the paper, Johnson NE, Nash DB, Carpenter CE, Sistek CJ. Ondansetron: costs and resource utilization in a us teaching hospital setting. Pharmacoeconomics 1993;31:471-81.